Behind Oslo's pharmaceutical supply chain: a $59M Indian connection

Deep in the hills of Himachal Pradesh, a remarkable industrial tale unfolds. India's pharmaceutical exports surged to $27.9 billion in 2023-24—a 9.67% jump despite global headwinds. Yet hidden within these macro figures lies a specialized story of dominance: India supplies over 91% of Norway's cyclic amides market, a $64.8 million trade flow worth $59.2 million to Indian manufacturers.

These are not household names—cyclic amides and their derivatives. The compounds serve as critical pharmaceutical intermediates, the molecular building blocks from which life-saving medicines emerge. The Trade and Economic Partnership Agreement (TEPA) between India and Norway's EFTA bloc entered force on October 1, 2025, promising to eliminate tariffs on most industrial products including these specialized chemicals.

But this is no sudden windfall. The data reveals India's overwhelming grip on Norway's market—controlling more than nine of every ten dollars spent on these compounds. TEPA incorporates product-specific rules of origin for chemical and pharmaceutical sectors, with certain chemical products previously facing tariffs up to 54% now seeing elimination.

The Molecule Makers of Gujarat and Hyderabad

The cyclic amides flowing to Norway originate from India's established pharmaceutical clusters. Divi's Laboratories Limited, headquartered in Hyderabad, is a leading manufacturer of active pharmaceutical ingredients, intermediates, and registered starting materials, supplying to over 100 countries. The company generates approximately $1.2 billion in revenue and exports to more than 100 countries.

Divi's manufactures generic APIs, intermediates, and nutraceutical ingredients, and offers custom synthesis of APIs to Big Pharma. Their services include design and development of synthesis routes for active pharmaceutical ingredients, advanced intermediates, and scalable production of linear, modified, and cyclic peptides.

The molecular precision required for cyclic amides—ring-structured compounds with specific nitrogen-containing linkages—demands sophisticated chemistry capabilities. The Baddi-Barotiwala-Nalagarh industrial belt hosts over 600 pharma companies and manufacturing units, contributing 35% of Asia's total pharmaceutical output.

"India is the sixth-largest chemical-producing country in the world and the third-largest producer in Asia, contributing 7% to India's Gross Domestic Product."

TEPA's Chemistry Dividend

The TEPA agreement is particularly advantageous for Indian exporters in organic chemicals, pharmaceuticals, and food processing industries targeting EFTA and Swiss markets. TEPA will boost manufacturing in pharmaceuticals, chemicals, and other sectors under "Make in India" and Atmanirbhar Bharat initiatives.

Norway's pharmaceutical market size is estimated at $3.13 billion in 2025, with cardiovascular medicines leading at 15.31% market share. For specialized chemical intermediates like cyclic amides, Norway represents a stable, regulated market where quality and regulatory compliance matter more than rock-bottom pricing.

The timing matters. March 2025 marked a high point for pharmaceutical exports reaching $3.68 billion—a 31.21% year-on-year growth compared to March 2024's $2.80 billion. India contributed 20% to global generic drug exports, with the pharmaceutical industry projected to grow at over 10% CAGR toward a $130 billion market by 2034.

The Employment Equation

Using pharmaceutical sector employment multipliers, this $59.2 million cyclic amides trade supports an estimated 2,070 direct jobs and 5,330 indirect positions across India's chemical and pharmaceutical value chain. The Baddi cluster generates over ₹60,000 crore annually, demonstrating how specialized chemical exports contribute to broader industrial employment.

Divi's employs approximately 20,100 highly trained professionals with around 700 scientists, illustrating the skilled workforce density these sectors create. With an estimated 30% women's employment share, the cyclic amides value chain supports approximately 621 direct female jobs and 1,599 indirect positions for women workers.

Baddi in Himachal Pradesh is one of India's largest pharmaceutical hubs, with major companies like Sun Pharma, Cipla, and Dr. Reddy's Laboratories establishing manufacturing units. The cluster effect amplifies employment impacts as companies share infrastructure, supply chains, and skilled labor pools.

Norway's appetite for Indian cyclic amides reflects a broader pharmaceuticals dependency. The USA, UK, South Africa, and France were India's top export destinations in FY25, with USA receiving $8.73 billion in pharmaceutical exports. Yet Norway's 91% reliance on Indian cyclic amides suppliers reveals how specialized chemical trade flows can achieve near-monopoly status through technical competence and cost efficiency.

As TEPA eliminates the final trade barriers, India's molecular manufacturers in Ahmedabad's GIDC, Hyderabad's Genome Valley, and Himachal's Baddi cluster are positioned to deepen their chemical grip on Norway's pharmaceutical supply chains. The cyclic amides flowing north represent more than trade statistics—they're the molecular foundation upon which Norway's medicine chest depends.